Image Place holder

Jessica Frakes, MD


Specialty: Radiation Oncology
Program: Radiation Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Jessica Frakes is an Assistant Member in the Department of Radiation Oncology at Moffitt Cancer Center. She received her MD from the University of South Florida Morsani College of Medicine. Dr. Frakes recently completed her Radiation Oncology Residency at the University of South Florida / Moffitt Cancer Center. Her clinical expertise is the use of radiation therapy to help patients diagnosed with gastrointestinal cancers, including esophageal, gastric, pancreatic, hepatobiliary, rectal and anal cancer. Dr. Frakes is experienced in the personalized use of advanced radiation techniques that include stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and liver-directed therapies such as radiation embolization. Her research interest includes improving outcomes and decreasing toxicity for the treatment of gastrointestinal cancers, with a strong focus on esophageal cancer. Dr. Frakes is a key member of the esophageal cancer research team, and she is dedicated to the advancement of multimodality treatments and the expansion of clinical trials.

Education & Training

Residency:

  • University of South Florida Moffitt Cancer Center - Radiation Oncology

Medical School:

  • University of South Florida Morasani School of Medicine - MD
Participating Trials

CLINICAL TRIAL 18941
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Condition: Gastrointestinal Tumor
Intervention: FOLFIRINOX; FOLFOX
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer. 2017 Oct;84:304-314. Pubmedid: 28863385.
  • Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 2017 Mar;56(3):391-397. Pubmedid: 27885876.
  • Oliver JA, Venkat P, Frakes JM, Klapman J, Harris C, Montilla-Soler J, Dhadham GC, Altazi BA, Zhang GG, Moros EG, Shridhar R, Hoffe SE, Latifi K. Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer. Endosc Int Open. 2017 Jun;5(6):E496-E504. Pubmedid: 28573183. Pmcid: PMC5451282.
  • Venkat PS, Hoffe SE, Frakes JM. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017 Jul;24(3). Pubmedid: 28975831.
  • Zhang DG, Feygelman V, Moros EG, Latifi K, Hoffe S, Frakes J, Zhang GG. Superficial and peripheral dose in compensator-based FFF beam IMRT. J Appl Clin Med Phys. 2017 Jan;18(1):151-156. Pubmedid: 28291940.
  • Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2017 Feb;28(2):254-259. Pubmedid: 27955832.
  • Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol. 2017 Aug. Pubmedid: 28833197.
  • Grass GD, Naghavi AO, Frakes JM, Perez BA, Dilling TJ. Treatment of Stage III Non-Small Cell Lung Cancer Patients With Concurrent Chemotherapy and Radiation (70 Gy): Equivalent or Superior to 60 or 74 Gy of RTOG 0617?. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E428-E429. Pubmedid: 27674664.
  • Mellon EA, Hoffe SE, Frakes JM, Strom T, Springett GM, Shridhar R, Centeno BA, Malafa MP, Chuong MD, Hodul PJ. Predictors and Survival for Pathologic Tumor Response Grade in Borderline Resectable and Locally Advanced Pancreatic Cancer Treated With Induction Chemotherapy and Neoadjuvant Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E165. Pubmedid: 27673949.
  • Mohammadi H, Abuodeh YA, Jin W, Frakes JM, Friedman M, Biebel B, Choi J, El-Haddad GE, Kis B, Sweeney J, Kim R, Pimiento JM, Malafa MP, Anaya D, Hoffe SE. Using the ALBI Grade as a Prognostic Marker for Radioembolization of Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E194-E195.
  • Glazer ES, Neill KG, Frakes JM, Coppola D, Hodul PJ, Hoffe SE, Pimiento JM, Springett GM, Malafa MP. Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. Cancer Control. 2016 Oct;23(4):446-454. Pubmedid: 27842335.
  • Jin W, Mellon EA, Hoffe SE, Frakes JM, Springett GM, Centeno BA, Kim R, Mahipal A, Pimiento JM, Malafa MP, Latifi K. Does Metabolic Tumor Volume Predict Tumor Regression Grade After Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer?. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E195. Pubmedid: 27674030.
  • Naghavi AO, Strom T, Abuodeh YA, Frakes JM, Ahmed KA, Harrison LB, Trotti A, Caudell JJ. Risk Factors for Recurrence in Human Papillomavirus-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E372-E373. Pubmedid: 27674513.
  • Naghavi AO, Strom TJ, Ahmed KA, Echevarria MI, Abuodeh YA, Venkat PS, Frakes JM, Harrison LB, Trotti AM, Caudell JJ. Management of Oropharyngeal Cancer in the HPV Era. Cancer Control. 2016 Jul;23(3):197-207. Pubmedid: 27556659.
  • Bustamante L, Frakes J, Hoffe S, Kim R. Investigational drugs for treating anal cancer and future perspectives. Expert Opin Inv Drug. 2016 Jan;25(1):51-62. Pubmedid: 26560877.
  • Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer. 2016 Feb;122(4):634-641. Pubmedid: 26565997.
  • Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol. 2016 Dec;22(47):10406-10414. Pubmedid: 28058021. Pmcid: PMC5175253.
  • Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA, Frakes JM, Eschrich SA, Torres-Roca JF. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Aug;95(5):1399-1404. Pubmedid: 27319288.
  • Kothari N, Mellon E, Hoffe SE, Frakes J, Shridhar R, Pimiento J, Meredith K, Tran ND, Saeed N, Almhanna K. Outcomes in patients with brain metastasis from esophageal carcinoma. J Gastrointest Oncol. 2016 Aug;7(4):562-569. Pubmedid: 27563446. Pmcid: PMC4963374.
  • Frakes JM, Strom TJ, Naghavi AO, Trotti A, Rao NG, McCaffrey JC, Otto KJ, Padhya T, Caudell JJ. Outcomes of mucosal melanoma of the head and neck. J Med Imaging Radiat Oncol. 2016 Apr;60(2):268-273. Pubmedid: 26597431.
  • Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiother Oncol. 2015 Oct;117(1):159-164. Pubmedid: 26235848.
  • Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol. 2015 Nov;112(6):597-602. Pubmedid: 26394724.
  • Frakes JM, Figura ND, Ahmed KA, Juan TH, Patel N, Latifi K, Sarangkasiri S, Strom TJ, Chinnaiyan P, Rao NG, Etame AB. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. J Neurosurg. 2015 Nov;123(5):1261-1267. Pubmedid: 26140482.
  • Frakes JM, Strom T, Springett GM, Hoffe SE, Balducci L, Hodul P, Malafa MP, Shridhar R. Resected pancreatic cancer outcomes in the elderly. Geriatr Oncol. 2015 Mar;6(2):127-132. Pubmedid: 25555451.
  • Arora D, Frakes J, Scott J, Opp D, Johnson C, Song J, Harris E. Incidental radiation to uninvolved internal mammary lymph nodes in breast cancer. Breast Cancer Res Treat. 2015 Jun;151(2):365-372. Pubmedid: 25929764.
  • Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015 Jul;54(7):979-985. Pubmedid: 25734581.